Printer Friendly

EUROPEAN PATENT OFFICE APPROVES CLAIMS FOR BIOGEN'S ALPHA INTERFERONS

 EUROPEAN PATENT OFFICE APPROVES CLAIMS FOR BIOGEN'S ALPHA INTERFERONS
 CAMBRIDGE, Mass., Nov. 2 /PRNewswire/ -- Biogen, Inc. (NASDAQ-NMS: BGEN) today announced that the European Patent Office's Technical Board of Appeal has upheld all the claims contained in Biogen's patent for genetically engineered alpha interferons. The decision, which is final and binding, was handed down Oct. 21, 1992.
 Alpha interferon is marketed worldwide under Biogen's patents by Schering-Plough Corporation under the tradename Intron(R) A. Schering- Plough now holds the largest worldwide alpha interferon market share and Intron(R) A is one of the world's fastest growing drugs. It is marketed in 58 countries for more than 15 anti-viral and anti-cancer indications and is used to treat some of the world's most widespread diseases, including hepatitis B, hepatitis C, genital warts and Karposi's sarcoma.
 "Intron(R) A is one of the largest and fastest growing biopharmaceutical products on the market today," said James L. Vincent, Biogen's chairman and chief executive officer. "This decision completes the legal process in the European Patent Office and reaffirms Biogen's fundamental patent position in alpha interferon."
 The Biogen patent is based on the pioneering scientific work of a founding Biogen scientist, Professor Charles Weissmann of the University of Zurich. It was the first novel genetically engineered drug to receive market approval. In handing down its decision, the Technical Board of Appeal dismissed an appeal filed by Boehringer Ingelheim Pharma Ges.mbH, Boehringer Mannheim GmbH and Bender & Co. Ges.mbH. That appeal has sought to overturn a 1990 ruling by the European Patent Office's Opposition Division that the claims in Biogen's patent were patentable in all aspects, thereby giving Biogen complete patent approval.
 Biogen, Inc. headquartered in Cambridge, Mass., is a biopharmaceutical company principally engaged in developing and manufacturing drugs for human healthcare through genetic engineering. The company's revenues are generated from the worldwide sales by licensees of five products, including alpha interferon and hepatitis b vaccines and diagnostic products. Biogen is focused primarily on developing and testing products for the treatment of cardiovascular disease, inflammatory diseases, viral diseases, AIDS and certain cancers. Schering-Plough is a research-based pharmaceutical company engaged in the discovery, development, manufacture and marketing of pharmaceutical and health care products worldwide.
 -0- 11/2/92
 /CONTACT: Kathryn R. Bloom, 617-252-9851 (media contact), Amy S. Hedison, 617-252-9873 (financial contact), for Biogen/
 (BGEN) CO: Biogen ST: Massachusetts IN: MTC SU:


CH -- NE011 -- 1701 11/02/92 15:04 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 2, 1992
Words:402
Previous Article:MCA HOME VIDEO PRESIDENT ROB BLATTNER KILLED IN PLANE CRASH
Next Article:LIFE USA HOLDING, INC. REPORTS THAT ONE-TIME OCCURRENCES MAY INCREASE FOURTH QUARTER EARNINGS -- ANNOUNCES POSSIBLE ACQUISITION
Topics:


Related Articles
ROCHE INTERFERON PATENT REEXAMINATION CONCLUDED BY PATENT AND TRADEMARK OFFICE
Biogen Announces That U.K. House Of Lords Rules That British Hepatitis B Patent Is Invalid
Schering-Plough Files Patent Infringement Suit Against Amgen on INFERGEN
Biogen Announces Favorable Decision Affecting Lawsuit Related to European Hepatitis B Patent Extension
Viragen Receives Japanese Patent; Korea Issues Similar Patent
Biogen Announces That It Has Opposed Rentschler's European Beta Interferon Patent.
Transkaryotic announces victory in Genzyme patent litigation.
European Patent Office affirms revocation of Serono gene.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters